Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.56 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.34 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.34 |
| ▸ | INSR | P06213 | 3/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042556 | 0.87 | MAPKAPK5 (0.61) | MAPKAPK5KDM1AINSRALKRPS6KA3 | |
| SCHEMBL1046703 | 0.85 | MAPKAPK5 (0.75) | MAPKAPK5PTK6BMPR1BKDRBMPR1A | |
| SCHEMBL10134492 | 0.84 | MAPKAPK5 (0.55) | MAPKAPK5PTK6 | |
| SCHEMBL1045465 | 0.82 | MAPKAPK5 (0.60) | MAPKAPK5KDM1AFGFR1CDK2 | |
| SCHEMBL1044238 | 0.82 | MAPKAPK5 (0.39) | MAPKAPK5KDM1AFGFR1JAK2MITF | |
| SCHEMBL1047015 | 0.81 | MAPKAPK5 (0.57) | MAPKAPK5BMPR1BKDRBMPR1AACVR1B | |
| SCHEMBL1044218 | 0.81 | MAPKAPK5 (0.44) | MAPKAPK5KDM1AINSRALKJAK2 | |
| SCHEMBL1047621 | 0.80 | KDM1A (0.40) | MAPKAPK5KDM1AALKFGFR1CDK2 | |
| SCHEMBL2218746 | 0.78 | MAPKAPK5 (0.78) | MAPKAPK5PTK6BMPR1BKDRBMPR1A | |
| SCHEMBL1399885 | 0.77 | MAPKAPK5 (0.41) | MAPKAPK5KDM1AFGFR1JAK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | claimed |
| EP-2086540-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-08-12 | — | — | EP | claimed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | claimed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | claimed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| EP-2086540-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 15/4885KDM1A 2801/4885PTK6 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.